Guías y evidencia
Lo que recomiendan las guías y lo que demuestran los estudios, separando siempre lo aprobado de lo que se investiga.
Todas las fuentes citadas en el ESPACIO, en formato Vancouver, con DOI y PMID verificados, filtrables por tema y descargables para un gestor bibliográfico.
La evidencia en el tiempo: los artículos y guías citados en este ESPACIO, por año (1 anteriores a 1990, fuera del eje)
510152025301111321216242411495861331312729172119901995200020052010201520202025La lista se hace sola con lo que citan las páginas de este ESPACIO y se descarga en RIS.
Artículos y guías en PubMed (190)
- Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation. 2015;132(21):2037-99. doi:10.1161/CIR.0000000000000329 · PMID 26534956G1
- Aggarwal V, Giri J, Visovatti SH, Mahmud E, Matsubara H, Madani M, et al. Status and Future Directions for Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease With and Without Pulmonary Hypertension: A Scientific Statement From the American Heart Association. Circulation. 2024;149(15):e1090-e1107. doi:10.1161/CIR.0000000000001197 · PMID 38450477C10G1
- Alonso-Gonzalez R, Lopez-Guarch CJ, Subirana-Domenech MT, Ruíz JMO, González IO, Cubero JS, et al. Pulmonary hypertension and congenital heart disease: An insight from the REHAP National Registry. Int J Cardiol. 2015;184:717-723. doi:10.1016/j.ijcard.2015.02.031 · PMID 25781723G3
- Ameri P, Mercurio V, Pollesello P, Anker MS, Backs J, Bayes-Genis A, et al. A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function. Eur J Heart Fail. 2024;26(4):707-729. doi:10.1002/ejhf.3236 · PMID 38639017G1H3
- Appenzeller P, Lichtblau M, Berlier C, Aubert JD, Azzola A, Fellrath JM, et al. Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry. Pulm Circ. 2022;12(1):e12001. doi:10.1002/pul2.12001 · PMID 35506112G3
- Armstrong I, Billings C, Kiely DG, Yorke J, Harries C, Clayton S, et al. The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients. BMC Pulm Med. 2019;19(1):67. doi:10.1186/s12890-019-0827-5 · PMID 30898139D1
- Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425-34. doi:10.7326/0003-4819-132-6-200003210-00002 · PMID 10733441G2I1
- Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376-87. doi:10.1378/chest.09-1140 · PMID 19837821G3
- Barberà JA, Escribano P, Morales P, Gómez MA, Oribe M, Martínez A, et al. Standards of care in pulmonary hypertension. Consensus Statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Cardiology (SEC). Arch Bronconeumol. 2008;44(2):87-99. doi:10.1157/13115748 · PMID 18361875G1
- Barberà JA, Román A, Gómez-Sánchez MÁ, Blanco I, Otero R, López-Reyes R, et al. Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. Arch Bronconeumol (Engl Ed). 2018;54(4):205-215. doi:10.1016/j.arbres.2017.11.014 · PMID 29472044G1
- Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-301. doi:10.1056/NEJM199602013340504 · PMID 8532025G2I1
- Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014;129(19):1914-23. doi:10.1161/CIRCULATIONAHA.113.005698 · PMID 24637559I1
- Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest. 2019;156(2):323-337. doi:10.1016/j.chest.2019.02.004 · PMID 30772387G3
- Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, et al. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest. 2021;159(1):337-346. doi:10.1016/j.chest.2020.08.2069 · PMID 32882243B3G3
- Benza RL, Adamson PB, Bhatt DL, Frick F, Olsson G, Bergh N, et al. CS1, a controlled-release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial. Pulm Circ. 2024;14(1):e12323. doi:10.1002/pul2.12323 · PMID 38174159G5
- Bermejo J, Yotti R, García-Orta R, Sánchez-Fernández PL, Castaño M, Segovia-Cubero J, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018;39(15):1255-1264. doi:10.1093/eurheartj/ehx700 · PMID 29281101G2H3I1
- Boucly A, Weatherald J, Savale L, Jaïs X, Cottin V, Prevot G, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2). doi:10.1183/13993003.00889-2017 · PMID 28775050G3
- Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prévot G, et al. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur Respir J. 2022;59(6). doi:10.1183/13993003.02419-2021 · PMID 34737227B3B4C4G3H5
- Boucly A, Beurnier A, Turquier S, Jevnikar M, de Groote P, Chaouat A, et al. Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension. Eur Respir J. 2024;64(3). doi:10.1183/13993003.00197-2024 · PMID 38663975C9
- Bravo-Marqués R, Rivas-Ruiz F, Tenes A, Becerra-Muñoz VM, Gutierrez-Ortiz E, de Miguel IM, et al. New phenotype and outcomes in connective tissue disease-associated pulmonary arterial hypertension: relevance of age-related comorbidities. Rheumatology (Oxford). 2026;65(3). doi:10.1093/rheumatology/keag105 · PMID 41758914G3H2
- Burkhoff D, Borlaug BA, Shah SJ, Zolty R, Tedford RJ, Thenappan T, et al. Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial. JACC Heart Fail. 2021;9(5):360-370. doi:10.1016/j.jchf.2021.01.015 · PMID 33839076G5
- Bäck M, Wilhelm M, Marcin T, Machado FVC, Sandberg A, Buccheri S, et al. 2026 ESC Guidelines on cardiac rehabilitation. Eur Heart J. 2026;47(39):5631-5729. doi:10.1093/eurheartj/ehag099 · PMID 42661418C6
- Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E, et al. Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort. Circulation. 2016;133(18):1761-71. doi:10.1161/CIRCULATIONAHA.115.019470 · PMID 27052413C10
- Carmona Segovia ADM, Becerra-Muñoz VM, Jiménez Arjona MJ, Naranjo Velasco V, Ochoa N, Barberà JA, et al. Real-life use of validated quality of life questionnaires in patients with pulmonary arterial hypertension in Spain: a cross-sectional study. Eur J Cardiovasc Nurs. 2025;24(7):1172-1174. doi:10.1093/eurjcn/zvaf108 · PMID 40622849G3
- Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119-23. doi:10.1016/S0140-6736(01)06250-X · PMID 11597664G2I1
- Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JSR, Grünig E, et al. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2021;78(14):1393-1403. doi:10.1016/j.jacc.2021.07.057 · PMID 34593120C4G2I1
- Chin KM, Gaine SP, Gerges C, Jing ZC, Mathai SC, Tamura Y, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4). doi:10.1183/13993003.01325-2024 · PMID 39209476C4C5C7G1I1
- Church C, Molina-Molina M, Arias-Guillén M, Muchmore P, Lavon BR, Backer J, et al. A Phase 2 Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease. Pulm Circ. 2026;16(2):e70322. doi:10.1002/pul2.70322 · PMID 42306238G5
- Corrigendum to: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2023;44(15):1312. doi:10.1093/eurheartj/ehad005 · PMID 36821743G1
- Creager MA, Barnes GD, Giri J, Mukherjee D, Jones WS, Burnett AE, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(13):1626-1710. doi:10.1016/j.jacc.2025.11.005 · PMID 41712898B1C10
- Cruz-Utrilla A, Gallego-Zazo N, Tenorio-Castaño JA, Guillén I, Torrent-Vernetta A, Moya-Bonora A, et al. Clinical Implications of the Genetic Background in Pediatric Pulmonary Arterial Hypertension: Data from the Spanish REHIPED Registry. Int J Mol Sci. 2022;23(18). doi:10.3390/ijms231810433 · PMID 36142358G3
- Cruz-Utrilla A, Gallego-Zazo N, Pérez-Olivares C, Hernández-González I, Bedate P, Martínez Meñaca A, et al. Usefulness of genetics for clinical reclassification and refinement of prognostic stratification in pulmonary arterial hypertension. Rev Esp Cardiol (Engl Ed). 2023;76(6):460-467. doi:10.1016/j.rec.2022.11.002 · PMID 36403940G3
- Cruz-Utrilla A, Cantero-Acedo Á, Tenes A, Enguita AB, Delgado-Jiménez JF, López-Meseguer M, et al. Pulmonary arterial hypertension associated with exposure to toxic rapeseed oil. ERJ Open Res. 2025;11(6). doi:10.1183/23120541.00720-2025 · PMID 41473551G3H2
- Dardi F, Boucly A, Benza R, Frantz R, Mercurio V, Olschewski H, et al. Risk stratification and treatment goals in pulmonary arterial hypertension. Eur Respir J. 2024;64(4). doi:10.1183/13993003.01323-2024 · PMID 39209472G1
- Dardi F, McCullagh B, Ferreira F, Meandzija M, Stulnig G, Neill W, et al. Delays in the diagnosis and management of pulmonary arterial hypertension: a simulated patient cases study across four European countries. ERJ Open Res. 2026;12(5). doi:10.1183/23120541.01693-2025 · PMID 42682869D1
- De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025;46(43):4462-4568. doi:10.1093/eurheartj/ehaf193 · PMID 40878294C6G1
- de Perrot M, Gopalan D, Jenkins D, Lang IM, Fadel E, Delcroix M, et al. Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. J Heart Lung Transplant. 2021;40(11):1301-1326. doi:10.1016/j.healun.2021.07.020 · PMID 34420851G1
- del Cerro Marín MJ, Sabaté Rotés A, Rodriguez Ogando A, Mendoza Soto A, Quero Jiménez M, Gavilán Camacho JL, et al. Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry. Am J Respir Crit Care Med. 2014;190(12):1421-9. doi:10.1164/rccm.201406-1052OC · PMID 25379685G3
- Del Pozo R, Blanco I, Hernández-González I, López-Meseguer M, López-Reyes R, Lázaro-Salvador M, et al. Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry. Int J Cardiol. 2019;275:158-164. doi:10.1016/j.ijcard.2018.10.012 · PMID 30316648G3
- Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D'Armini AM, Snijder R, et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation. 2016;133(9):859-71. doi:10.1161/CIRCULATIONAHA.115.016522 · PMID 26826181C10G3
- Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021;57(6). doi:10.1183/13993003.02828-2020 · PMID 33334946G1
- Delcroix M, Pepke-Zaba J, D'Armini AM, Fadel E, Guth S, Hoole SP, et al. Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy. Circulation. 2024;150(17):1354-1365. doi:10.1161/CIRCULATIONAHA.124.068610 · PMID 39286890G3
- Diener J, Soni H, Booe J, Darce J, MacBain Z, Thulasiraman S, et al. Development of a long-acting relaxin for the treatment of pulmonary hypertension. Br J Pharmacol. 2026;183(16):5062-5081. doi:10.1111/bph.70498 · PMID 42173817G5
- DuBrock HM, Wagner TE, Carlson K, Carpenter CL, Awasthi S, Attia ZI, et al. An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension. Eur Respir J. 2024;64(1). doi:10.1183/13993003.00192-2024 · PMID 38936966G5
- Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P, Mairuhu AT, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. 2017;49(2). doi:10.1183/13993003.01792-2016 · PMID 28232411C10
- Ersbøll MK, Kjærgaard J, Waidtløw K, Køber L, Gustafsson F, Kiely DG, et al. Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial. J Heart Lung Transplant. 2026;45(12):1983-1994. doi:10.1016/j.healun.2026.07.008 · PMID 42671364G5
- Escribano-Subias P, Blanco I, López-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012;40(3):596-603. doi:10.1183/09031936.00101211 · PMID 22362843D1G3H2
- Escribano-Subías P, Del Pozo R, Román-Broto A, Domingo Morera JA, Lara-Padrón A, Elías Hernández T, et al. Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective. Int J Cardiol. 2016;203:938-44. doi:10.1016/j.ijcard.2015.11.039 · PMID 26618257D1G3H2
- Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043-54. doi:10.1378/chest.15-0300 · PMID 26066077G3
- Frantz RP, McLaughlin VV, Sahay S, Escribano Subías P, Zolty RL, Benza RL, et al. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2024;12(7):523-534. doi:10.1016/S2213-2600(24)00072-9 · PMID 38705167G5
- Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-57. doi:10.1056/NEJMoa050010 · PMID 16291984G2I1
- Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48-54. doi:10.1161/CIRCULATIONAHA.106.630715 · PMID 16801459G2I1
- Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010-9. doi:10.1161/CIRCULATIONAHA.107.742510 · PMID 18506008G2I1
- Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093-100. doi:10.1016/S0140-6736(08)60919-8 · PMID 18572079G2I1
- Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894-903. doi:10.1161/CIRCULATIONAHA.108.839274 · PMID 19470885G2I1
- Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834-44. doi:10.1056/NEJMoa1413687 · PMID 26308684C4G2I1
- Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45(5):1314-22. doi:10.1183/09031936.00105914 · PMID 25657022G2I1
- Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317 · PMID 26320113G1
- Garcia AR, Blanco I, Ramon L, Pérez-Sagredo J, Guerra-Ramos FJ, Martín-Ontiyuelo C, et al. Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry. Respir Res. 2023;24(1):223. doi:10.1186/s12931-023-02531-1 · PMID 37715261G3
- García-Hernández FJ, Castillo-Palma MJ, Tolosa-Vilella C, Guillén-Del Castillo A, Rubio-Rivas M, Freire M, et al. Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry. Clin Rheumatol. 2019;38(4):1117-1124. doi:10.1007/s10067-018-4390-x · PMID 30535994G3H2
- Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, et al. Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation. 2019;139(1):51-63. doi:10.1161/CIRCULATIONAHA.118.033575 · PMID 30586694G2I1
- Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-29. doi:10.1056/NEJMoa1209657 · PMID 23883377C10G2I1
- Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330-40. doi:10.1056/NEJMoa1209655 · PMID 23883378G2I1
- Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study (artículo retractado). Lancet Respir Med. 2017;5(10):785-794. doi:10.1016/S2213-2600(17)30305-3 · PMID 28919201G2
- Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2024;12(4):e21-e30. doi:10.1016/S2213-2600(24)00027-4 · PMID 38548406C10G2I1
- Ghofrani HA, Leuchte HH, Al-Hiti H, Halank M, Jansa P, Lange T, et al. Phase 1b ATMOS trial of the inhaled sGC activator mosliciguat in patients with PAH/CTEPH. Thorax. 2026. doi:10.1136/thorax-2025-224583 · PMID 42728065G5
- Gomberg-Maitland M, Tedford RJ, Langleben D, Rosenkranz S, Miller B, Jones AD, et al. Sotatercept for Combined Post- and Precapillary Pulmonary Hypertension Associated With Heart Failure: Results From the Phase 2, Randomized, Placebo-Controlled CADENCE Study. Circulation. 2026;153(19):1446-1459. doi:10.1161/CIRCULATIONAHA.126.079918 · PMID 41904795G5
- Grünig E, MacKenzie A, Peacock AJ, Eichstaedt CA, Benjamin N, Nechwatal R, et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. Eur Heart J. 2021;42(23):2284-2295. doi:10.1093/eurheartj/ehaa696 · PMID 33232470C6
- Grünig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, et al. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2024;83(4):473-484. doi:10.1016/j.jacc.2023.10.045 · PMID 38267108G2I1
- Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124(2):164-74. doi:10.1161/CIRCULATIONAHA.110.983866 · PMID 21709061G2H3
- Guignabert C, Aman J, Bonnet S, Dorfmüller P, Olschewski AJ, Pullamsetti S, et al. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. Eur Respir J. 2024;64(4). doi:10.1183/13993003.01095-2024 · PMID 39209474H1
- Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. doi:10.1093/eurheartj/ehac270 · PMID 36017553C6
- Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019;38(9):879-901. doi:10.1016/j.healun.2019.06.022 · PMID 31495407G1
- Hemnes AR, Celermajer DS, D'Alto M, Haddad F, Hassoun PM, Prins KW, et al. Pathophysiology of the right ventricle and its pulmonary vascular interaction. Eur Respir J. 2024;64(4). doi:10.1183/13993003.01321-2024 · PMID 39209482H1
- Hill NS, Gillies H, Chakinala MM, Feldman JP, Hoeper MM, Jing ZC, et al. Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2026;212(4):802-812. doi:10.1093/ajrccm/aamaf128 · PMID 41738079G5
- Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015;36(38):2565-73. doi:10.1093/eurheartj/ehv336 · PMID 26188003G2H3
- Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128-38. doi:10.1161/CIRCULATIONAHA.112.000765 · PMID 23403476G5
- Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013;168(2):871-80. doi:10.1016/j.ijcard.2012.10.026 · PMID 23164592G3
- Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2). doi:10.1183/13993003.00740-2017 · PMID 28775047G3
- Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(6):573-584. doi:10.1016/S2213-2600(20)30532-4 · PMID 33773120C4G2I1
- Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60(1). doi:10.1183/13993003.02311-2021 · PMID 34737226B3B4G3
- Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023;388(16):1478-1490. doi:10.1056/NEJMoa2213558 · PMID 36877098C4C5G2I1
- Hoeper MM, Ewert R, Jansa P, Sirenko Y, Skride A, Balagtas C, et al. Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension. Circulation. 2024;149(25):1949-1959. doi:10.1161/CIRCULATIONAHA.123.068107 · PMID 38752352I1
- Hoeper MM, Preston IR, Gomberg-Maitland M, Waxman AB, Shi Y, Lin J, et al. Pericardial effusion in sotatercept phase 3 trials: insights from STELLAR and ZENITH. Eur Respir J. 2025;66(3). doi:10.1183/13993003.00768-2025 · PMID 40774811C5I2
- Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428-46. doi:10.1183/09031936.00150314 · PMID 25359355D4
- Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353-9. doi:10.1183/09031936.04.00028404 · PMID 15358690G2
- Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-30. doi:10.1164/rccm.200510-1668OC · PMID 16456139G3
- Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156-63. doi:10.1161/CIRCULATIONAHA.109.911818 · PMID 20585011G3
- Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021;384(13):1204-1215. doi:10.1056/NEJMoa2024277 · PMID 33789009C5G2
- Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237 · PMID 36017548B1B3B4B6B7C3C4C6C7C8C9C10D1D4E3G1G5H1H3H4H5I1I2J2
- Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1). doi:10.1183/13993003.00879-2022 · PMID 36028254B4B6C3C4C5C6C7C8C9C10E3G1H1H2H3H5I1I2
- Humbert M, Hassoun PM, Chin KM, Bortman G, Patel MJ, La Rosa C, et al. MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study. Eur Respir J. 2024;64(5). doi:10.1183/13993003.01110-2024 · PMID 39255991G5
- Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, et al. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025;392(20):1987-2000. doi:10.1056/NEJMoa2415160 · PMID 40167274B3C4C5G2I1
- Ivy D, Bonnet D, Berger RMF, Meyer GMB, Baygani S, Li B, et al. Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study. Pulm Circ. 2021;11(3):20458940211024955. doi:10.1177/20458940211024955 · PMID 34234945I1
- Ivy D, Rosenzweig EB, Abman SH, Beghetti M, Bonnet D, Douwes JM, et al. Embracing the challenges of neonatal and paediatric pulmonary hypertension. Eur Respir J. 2024;64(4). doi:10.1183/13993003.01345-2024 · PMID 39209483G1
- Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52(25):2127-34. doi:10.1016/j.jacc.2008.08.059 · PMID 19095129G2I1
- Jaïs X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med. 2022;10(10):961-971. doi:10.1016/S2213-2600(22)00214-4 · PMID 35926542C10G2I1
- Jenkins DP, Cerovic S, Csonka D, Ghofrani HA, Guth S, Heresi GA, et al. Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2026;45(3):442-451. doi:10.1016/j.healun.2025.11.014 · PMID 41297734C10G2G5I1
- Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624-33. doi:10.1161/CIRCULATIONAHA.112.124388 · PMID 23307827G2
- Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study. Cardiology. 2008;109(4):273-80. doi:10.1159/000107791 · PMID 17873492G2
- Kan J, Zhang H, Xie D, Wei Y, Zhang J, Zhang C, et al. A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial. EuroIntervention. 2023;19(8):684-694. doi:10.4244/EIJ-D-23-00349 · PMID 37458100G5
- Kawakami T, Matsubara H, Shinke T, Abe K, Kohsaka S, Hosokawa K, et al. Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial. Lancet Respir Med. 2022;10(10):949-960. doi:10.1016/S2213-2600(22)00171-0 · PMID 35926544C10
- Khilzi K, Blanco I, Piccari L, Barberà JA, López-Reyes R, Otero-González I, et al. Smoking exposure on diagnosis and survival of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from REHAP registry. Pulmonology. 2026;32(1):2640669. doi:10.1080/25310429.2026.2640669 · PMID 41804599G3
- Khou V, Anderson JJ, Strange G, Corrigan C, Collins N, Celermajer DS, et al. Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry. Respirology. 2020;25(8):863-871. doi:10.1111/resp.13768 · PMID 31997504D1
- Kim NH, Channick R, Delcroix M, Madani M, Pepke-Zaba J, Borissoff JI, et al. Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial). Eur Respir J. 2024;64(4). doi:10.1183/13993003.00193-2024 · PMID 39326918G5
- Kim NH, D'Armini AM, Delcroix M, Jaïs X, Jevnikar M, Madani MM, et al. Chronic thromboembolic pulmonary disease. Eur Respir J. 2024;64(4). doi:10.1183/13993003.01294-2024 · PMID 39209473C10G1
- Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030 · PMID 30660783G1
- Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405 · PMID 31504429C10
- Kovacs G, Bartolome S, Denton CP, Gatzoulis MA, Gu S, Khanna D, et al. Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. 2024;64(4). doi:10.1183/13993003.01324-2024 · PMID 39209475B6B7C7C9D1G1G5H4H5
- Kovacs G, Zeder K, Humbert M, Condliffe R, Toews I, Boucly A, et al. European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension. Eur Respir J. 2026. doi:10.1183/13993003.01178-2026 · PMID 42705705B4C3C4C5C7C9D1D4E3G1G5H1H4H5I1I2
- Kramm T, Wilkens H, Fuge J, Schäfers HJ, Guth S, Wiedenroth CB, et al. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. Clin Res Cardiol. 2018;107(7):548-553. doi:10.1007/s00392-018-1215-5 · PMID 29450722H2
- Kylhammar D, Kjellström B, Hjalmarsson C, Jansson K, Nisell M, Söderberg S, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175-4181. doi:10.1093/eurheartj/ehx257 · PMID 28575277G3
- Køber L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;47(38):5346-5457. doi:10.1093/eurheartj/ehag100 · PMID 42661420B1H3
- Lazaro Salvador M, Quezada Loaiza CA, Rodríguez Padial L, Barberá JA, López-Meseguer M, López-Reyes R, et al. Portopulmonary hypertension: prognosis and management in the current treatment era - results from the REHAP registry. Intern Med J. 2021;51(3):355-365. doi:10.1111/imj.14751 · PMID 31943676G3H2
- Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012;186(8):790-6. doi:10.1164/rccm.201203-0383OC · PMID 22798320G3
- López-Gude MJ, Blanco I, Benito-Arnáiz V, Castellà M, Escribano-Subías P, Martin C, et al. Pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension: the Spanish experience. Ann Cardiothorac Surg. 2022;11(2):151-160. doi:10.21037/acs-2021-pte-18 · PMID 35433371G3H2
- López-Meseguer M, Quezada CA, Ramon MA, Lázaro M, Dos L, Lara A, et al. Lung and heart-lung transplantation in pulmonary arterial hypertension. PLoS One. 2017;12(11):e0187811. doi:10.1371/journal.pone.0187811 · PMID 29161284G3H2
- Maron BA, Bortman G, De Marco T, Huston JH, Lang IM, Rosenkranz SH, et al. Pulmonary hypertension associated with left heart disease. Eur Respir J. 2024;64(4). doi:10.1183/13993003.01344-2024 · PMID 39209478G1G5
- Martí D, Gómez V, Escobar C, Wagner C, Zamarro C, Sánchez D, et al. Incidencia de hipertensión pulmonar tromboembólica crónica sintomática y asintomática. Arch Bronconeumol. 2010;46(12):628-33. doi:10.1016/j.arbres.2010.07.012 · PMID 20926172G3
- Martínez-Meñaca A, Cruz-Utrilla A, Mora-Cuesta VM, Luna-López R, Segura-de la Cal T, Flox-Camacho Á, et al. Simplified risk stratification based on cardiopulmonary exercise test: A Spanish two-center experience. Pulm Circ. 2024;14(1):e12342. doi:10.1002/pul2.12342 · PMID 38414916G3
- Martínez-Santos P, Velázquez-Martín MT, Barberá JA, Fernández Pérez C, López-Meseguer M, López-Reyes R, et al. Chronic thromboembolic pulmonary hypertension in Spain: a decade of change. Rev Esp Cardiol (Engl Ed). 2021;74(5):384-392. doi:10.1016/j.rec.2020.06.006 · PMID 32654945G3H2
- McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46(2):405-13. doi:10.1183/13993003.02044-2014 · PMID 26113687G2I1
- McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-619. doi:10.1016/j.jacc.2009.01.004 · PMID 19389575G1
- McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-22. doi:10.1016/j.jacc.2010.01.027 · PMID 20430262G2
- McLaughlin VV, Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, et al. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. N Engl J Med. 2025;393(16):1599-1611. doi:10.1056/NEJMoa2508170 · PMID 41025556C4C5G2I1
- McLaughlin VV, Solum D, Lachant D, Ataya A, Barberà JA, Meyer GB, et al. Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study. Lancet. 2026;408(10554):521-531. doi:10.1016/S0140-6736(26)01011-1 · PMID 42520828G5
- Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M, et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J. 2013;41(6):1302-7. doi:10.1183/09031936.00089212 · PMID 23143546C6
- Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098. doi:10.1056/NEJM198710223171717 · PMID 3657876B3
- Mukherjee M, Rudski LG, Addetia K, Afilalo J, D'Alto M, Freed BH, et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2025;38(3):141-186. doi:10.1016/j.echo.2025.01.006 · PMID 40044341C7G1
- Narang N, Gore MO, Snell PG, Ayers CR, Lorenzo S, Carrick-Ranson G, et al. Accuracy of estimating resting oxygen uptake and implications for hemodynamic assessment. Am J Cardiol. 2012;109(4):594-8. doi:10.1016/j.amjcard.2011.10.010 · PMID 22100029B3
- Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med. 2019;7(9):780-790. doi:10.1016/S2213-2600(19)30250-4 · PMID 31416769G2H3I1
- Nathan SD, Argula R, Trivieri MG, Aziz S, Gay E, Medarov B, et al. Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results. Eur Respir J. 2024;63(6). doi:10.1183/13993003.00172-2024 · PMID 38811045G5
- Nathan SD, Rajicic N, Dudenhofer R, Hussain R, Argula R, Bandyopadhyay D, et al. Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled Trial. Ann Am Thorac Soc. 2024;21(12):1661-1669. doi:10.1513/AnnalsATS.202406-662OC · PMID 39141673G5
- Nathan SD, Behr J, Cottin V, Lancaster L, Smith P, Deng CQ, et al. Study Design and Rationale for the TETON-PPF Phase 3, Randomized, Controlled Clinical Trial of Inhaled Treprostinil in the Treatment of Progressive Pulmonary Fibrosis. CHEST Pulm. 2025;3(2):100124. doi:10.1016/j.chpulm.2024.100124 · PMID 42548323G5
- Nathan SD, Smith P, Deng C, De Salvo M, Wuyts W, Pavie-Gallegos J, et al. Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2026;395(2):127-137. doi:10.1056/NEJMoa2512911 · PMID 41812190G5
- Nathan SD, Smith P, Deng C, Golden J, Reynaud-Gaubert M, Farr G, et al. Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2026. doi:10.1093/ajrccm/aamag507 · PMID 42776606G5
- Nathan SD, Smith P, Deng C, King CS, De Salvo M, Weigt SS, et al. Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2026;395(2):115-126. doi:10.1056/NEJMoa2501488 · PMID 42149993G5
- Navas P, Tenorio J, Quezada CA, Barrios E, Gordo G, Arias P, et al. Molecular Analysis of BMPR2, TBX4, and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension. Rev Esp Cardiol (Engl Ed). 2016;69(11):1011-1019. doi:10.1016/j.rec.2016.03.029 · PMID 27453251G3
- Navas Tejedor P, Palomino Doza J, Tenorio Castaño JA, Enguita Valls AB, Rodríguez Reguero JJ, Martínez Meñaca A, et al. Variable Expressivity of a Founder Mutation in the EIF2AK4 Gene in Hereditary Pulmonary Veno-occlusive Disease and Its Impact on Survival. Rev Esp Cardiol (Engl Ed). 2018;71(2):86-94. doi:10.1016/j.rec.2017.03.034 · PMID 28697925G3
- Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322-9. doi:10.1056/NEJMoa020204 · PMID 12151469G2I1
- Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124(18):1973-81. doi:10.1161/CIRCULATIONAHA.110.015008 · PMID 21969018D1G3
- Preston IR, Badesch D, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, et al. A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. Eur Respir J. 2025;66(1). doi:10.1183/13993003.01435-2024 · PMID 39978862C5G2
- Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809-18. doi:10.1056/NEJMoa1213917 · PMID 23984728C4G2H5I1
- Quezada Loaiza CA, Velázquez Martín MT, Jiménez López-Guarch C, Ruiz Cano MJ, Navas Tejedor P, Carreira PE, et al. Trends in Pulmonary Hypertension Over a Period of 30 Years: Experience From a Single Referral Centre. Rev Esp Cardiol (Engl Ed). 2017;70(11):915-923. doi:10.1016/j.rec.2016.12.044 · PMID 28454887G3H2
- Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158(9):641-9. doi:10.7326/0003-4819-158-9-201305070-00003 · PMID 23648946G2H3I1
- Rahaghi FF, Humbert M, Hoeper MM, White RJ, Frantz RP, Hassoun PM, et al. Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients. Lancet Respir Med. 2025;13(4):364-370. doi:10.1016/S2213-2600(24)00425-9 · PMID 39987941G5
- Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268-77. doi:10.1001/jama.2013.2024 · PMID 23478662I1
- Rodríguez-Chiaradía DA, Torres-Castro R, Piccari L, García-Ortega A, Perez-Peñate GM, de Miguel-Díez J, et al. A Systematic Review and Expert Recommendation on the Diagnosis of Pulmonary Hypertension Associated With Lung Disease: A Position Paper of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol. 2025;61(10):617-625. doi:10.1016/j.arbres.2025.03.015 · PMID 40222881G1
- Rothman AMK, Villar SS, Middleton J, Roussakis AA, Varian F, Zafar H, et al. Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study. Am J Respir Crit Care Med. 2025;211(6):1018-1027. doi:10.1164/rccm.202410-1929OC · PMID 40080796G5
- Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112(7):485-91. doi:10.7326/0003-4819-112-7-485 · PMID 2107780G2I1
- Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903. doi:10.1056/NEJMoa012212 · PMID 11907289G2I1
- Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med. 2019;7(3):239-248. doi:10.1016/S2213-2600(18)30367-9 · PMID 30477763C10G2I1
- Sahay S, Villasmil Hernandez N, Wang F, Wooten M, Nguyen DT, Fauvel C, et al. Comparison Between REVEAL Lite 2 and COMPERA 2.0 for Risk Stratification in Pulmonary Arterial Hypertension. Chest. 2024;166(2):373-387. doi:10.1016/j.chest.2024.02.052 · PMID 38447640G3
- Sahay S, Villasmil Hernandez N, Al Aaraj Y, Argula RG, Bernardo RJ, Chavarria M, et al. Pericardial effusions and sotatercept therapy in pulmonary arterial hypertension: a multicentre, real-world experience. Eur Respir J. 2025;66(4). doi:10.1183/13993003.01040-2025 · PMID 40774808C5
- Salvador ML, Rodríguez-Padial L, Soto Abánades C, Cruz Utrilla A, Barberá Mir JA, López-Meseguer M, et al. Management and prognosis of HIV-associated pulmonary arterial hypertension: 20 Years of evidence from the REHAP registry. J Intern Med. 2022;292(1):116-126. doi:10.1111/joim.13468 · PMID 35184348G3H2
- SEC Working Group for the 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension and SEC Guidelines Committe. Comments on the 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol (Engl Ed). 2023;76(5):294-300. doi:10.1016/j.rec.2022.11.001 · PMID 36379365G1
- Shlobin OA, Adir Y, Barbera JA, Cottin V, Harari S, Jutant EM, et al. Pulmonary hypertension associated with lung diseases. Eur Respir J. 2024;64(4). doi:10.1183/13993003.01200-2024 · PMID 39209469G5
- Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800-4. doi:10.1164/ajrccm.165.6.2106079 · PMID 11897647G2I1
- Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):5S-12S. doi:10.1016/j.jacc.2004.02.037 · PMID 15194173C7
- Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521-30. doi:10.7326/0003-4819-149-8-200810210-00004 · PMID 18936500G2I1
- Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Hoeper MM, Jansa P, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. 2015;45(5):1293-302. doi:10.1183/09031936.00087114 · PMID 25395036C10
- Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1). doi:10.1183/13993003.01913-2018 · PMID 30545968G1
- Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(26):2522-33. doi:10.1056/NEJMoa1503184 · PMID 26699168C4G2I1
- Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019;7(7):594-604. doi:10.1016/S2213-2600(19)30091-8 · PMID 31178422G2I1
- Sitbon O, Skride A, Feldman J, Sahay S, Shlobin OA, McLaughlin V, et al. Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial. Lancet Respir Med. 2024;12(11):865-876. doi:10.1016/S2213-2600(24)00226-1 · PMID 39307144G5
- Sitbon O, Boucly A, Weatherald J, Antigny F, Guignabert C, Jevnikar M, et al. Drugs targeting novel pathways in pulmonary arterial hypertension. Eur Respir J. 2025;66(2). doi:10.1183/13993003.01830-2024 · PMID 40341051G5
- Sitbon O, Sahay S, Escribano Subías P, Zolty RL, Kingrey JF, Ryan JJ, et al. Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study. Adv Ther. 2025;42(10):5104-5123. doi:10.1007/s12325-025-03297-2 · PMID 40788460G5
- Strange G, Gabbay E, Kermeen F, Williams T, Carrington M, Stewart S, et al. Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: The delay study. Pulm Circ. 2013;3(1):89-94. doi:10.4103/2045-8932.109919 · PMID 23662179D1
- Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014;146(2):449-475. doi:10.1378/chest.14-0793 · PMID 24937180G1
- Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383-1390. doi:10.1378/chest.11-2212 · PMID 22628490G2
- Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144(3):952-958. doi:10.1378/chest.12-2875 · PMID 23669822G2
- The Editors Of The Lancet Respiratory Medicine. Retraction and republication-Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2024;12(4):262-263. doi:10.1016/S2213-2600(24)00029-8 · PMID 38552648G2
- Tonelli AR, Aulak KS, Berro J, Highland KB. Activin pathway inhibition and rapid progression of malignancy in pulmonary arterial hypertension: A case series and hypothesis. Respir Med. 2026;263:109151. doi:10.1016/j.rmed.2026.109151 · PMID 42727657I2
- Torres-Castro R, Hinojosa W, Martínez-Meñaca A, Sala Llinas E, Jiménez Arjona J, Rueda Soriano J, et al. Epidemiology of supplemental oxygen in patients with pulmonary hypertension. Respirology. 2025;30(1):70-79. doi:10.1111/resp.14821 · PMID 39210654G3
- Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007;48(5):680-4. doi:10.2967/jnumed.106.039438 · PMID 17475953C10
- Ufnal M, Connolly K, Millegard M, Surkova E, Guazzi M, Bonderman D, et al. Relaxin mimetic in pulmonary hypertension associated with left heart disease: Design and rationale of Re-PHIRE. ESC Heart Fail. 2025;12(3):1956-1964. doi:10.1002/ehf2.15203 · PMID 39829393G5
- Vachiéry JL, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018;51(2). doi:10.1183/13993003.01886-2017 · PMID 29437943G2H3I1
- Valerio L, Mavromanoli AC, Barco S, Abele C, Becker D, Bruch L, et al. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J. 2022;43(36):3387-3398. doi:10.1093/eurheartj/ehac206 · PMID 35484821C10
- Velázquez M, Albarrán A, Hernández I, López-Gude MJ, Sarnago F, Martín R, et al. Balloon Pulmonary Angioplasty for Inoperable Patients With Chronic Thromboembolic Pulmonary Hypertension. Observational Study in a Referral Unit. Rev Esp Cardiol (Engl Ed). 2019;72(3):224-232. doi:10.1016/j.rec.2018.02.020 · PMID 29857972G3H2
- Velázquez Martín M, Gómez Menchero A, González Ferreiro R, Andrés Morist A, Maneiro Melón N, Escribano Subias P. Expert center and balloon pulmonary angioplasty network program in chronic thromboembolic pulmonary hypertension: safety and effectiveness of a pioneering experience. Rev Esp Cardiol (Engl Ed). 2024;77(6):490-493. doi:10.1016/j.rec.2023.12.012 · PMID 38280548C10G3
- Vitulo P, Stanziola A, Confalonieri M, Libertucci D, Oggionni T, Rottoli P, et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. J Heart Lung Transplant. 2017;36(2):166-174. doi:10.1016/j.healun.2016.04.010 · PMID 27329400G2H3
- Vizza CD, Jansa P, Teal S, Dombi T, Zhou D. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovasc Disord. 2017;17(1):239. doi:10.1186/s12872-017-0674-3 · PMID 28874133G2
- Vizza CD, Hoeper MM, Huscher D, Pittrow D, Benjamin N, Olsson KM, et al. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Chest. 2021;160(2):678-689. doi:10.1016/j.chest.2021.02.012 · PMID 33581097G3
- Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med. 2021;384(4):325-334. doi:10.1056/NEJMoa2008470 · PMID 33440084G2G5H3
- White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, et al. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. Am J Respir Crit Care Med. 2020;201(6):707-717. doi:10.1164/rccm.201908-1640OC · PMID 31765604G2
- Yaku H, Burkhoff D, Borlaug BA, Lala A, Butler J, Rich S, et al. Oral Levosimendan for the Treatment of Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction: Rationale and Design of the LEVEL Trial. J Card Fail. 2026;32(6):1059-1071. doi:10.1016/j.cardfail.2025.06.009 · PMID 40633684G5
- Yogeswaran A, Gall H, Fünderich M, Wilkins MR, Howard L, Kiely DG, et al. Comparison of Contemporary Risk Scores in All Groups of Pulmonary Hypertension: A Pulmonary Vascular Research Institute GoDeep Meta-Registry Analysis. Chest. 2024;166(3):585-603. doi:10.1016/j.chest.2024.03.018 · PMID 38508334G3
- Zhang H, Zhang J, Chen M, Xie DJ, Kan J, Yu W, et al. Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients With Combined Pre- and Post-Capillary Pulmonary Hypertension Associated With Left Heart Failure: The PADN-5 Study. JACC Cardiovasc Interv. 2019;12(3):274-284. doi:10.1016/j.jcin.2018.09.021 · PMID 30732732G5
- Zhang H, Wei Y, Zhang C, Yang Z, Kan J, Gu H, et al. Pulmonary Artery Denervation for Pulmonary Arterial Hypertension: A Sham-Controlled Randomized PADN-CFDA Trial. JACC Cardiovasc Interv. 2022;15(23):2412-2423. doi:10.1016/j.jcin.2022.09.013 · PMID 36121246G5
- Zhang H, Wang Q, Liang M, Chen X, Zhuang W, Cheng B, et al. Pulmonary Denervation for Heart Failure-Related Pulmonary Hypertension. N Engl J Med. 2026. doi:10.1056/NEJMoa2609056 · PMID 42670986G5
Fichas técnicas (CIMA, AEMPS) (20)
- Ficha técnica de ambrisentán (10 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 08451004B4C1C3C4C8H3I1I2
- Ficha técnica de ambrisentán y tadalafilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 91737C3I2
- Ficha técnica de bosentán (125 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 113832002B4C1C3C4C8H3I1I2
- Ficha técnica de epoprostenol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 81076B6C3D4I1I2
- Ficha técnica de epoprostenol (0,5 mg, polvo y disolvente para solución para perfusión). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 57757B4B6C1C3C4C8D4H3I1I2
- Ficha técnica de iloprost. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 61596C3I1
- Ficha técnica de iloprost. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 86227C3
- Ficha técnica de iloprost (10 µg/mL, solución para inhalación por nebulizador). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 86226B4B6C3C8D4H3I1I2
- Ficha técnica de macitentán (10 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 113893002B4C1C3C4C8C10H3I1I2
- Ficha técnica de macitentán y tadalafilo (10 mg/20 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1241859001B4C3C7C8I1I2
- Ficha técnica de riociguat (1 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 113907004B4B6C1C3C4C8C10H3I1I2
- Ficha técnica de selexipag (1.000 µg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1151083007B4C1C3C7C8H3I1I2
- Ficha técnica de sildenafilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 05318002C3I1
- Ficha técnica de sildenafilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 05318003C3I1
- Ficha técnica de sildenafilo (20 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 05318001B4B6C3C7C8H3I1I2
- Ficha técnica de sotatercept. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1241850001B4B6C1C3C4C7C8D4H3I1I2
- Ficha técnica de sotatercept. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1241850003C3I2
- Ficha técnica de tadalafilo (20 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 08476006B4B6C1C3C8H3I1I2
- Ficha técnica de treprostinil. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1191419001B6C3C10H3I1I2
- Ficha técnica de treprostinil (1 mg/mL, solución para perfusión). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 83745B4B6C3C4C8D4H3I1I2
Documentos oficiales (27)
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Ambrisentán. cima.aemps.esI2
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Bosentán. cima.aemps.esI2
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Combinación de macitentán y tadalafilo. cima.aemps.esI2
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Cuestionario. cima.aemps.esI2
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Instrucciones de uso. cima.aemps.esI2
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). IPT-347/V1/28022025: sotatercept en la HAP en clase funcional II-III. aemps.gob.es (PDF)C2
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). IPT-447/V1/08052026: sotatercept en la HAP en clase funcional II, III y IV. aemps.gob.es (PDF)C2
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Macitentán. cima.aemps.esI2
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Para el paciente. cima.aemps.esI2
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Para el profesional. cima.aemps.esI2
- Ministerio de Sanidad. BIFIMED: buscador de la información sobre la situación de financiación de los medicamentos. Consultado el 15/11/2026. sanidad.gob.esC2
- Ministerio de Sanidad. Centros del Sistema Nacional de Salud en las redes europeas de referencia (enero de 2026). sanidad.gob.es (PDF)J2
- Ministerio de Sanidad. Centros, servicios y unidades de referencia (CSUR) del área de cardiología y cirugía cardiaca. Consultado el 15/11/2026. sanidad.gob.esJ2
- Ministerio de Sanidad. CSUR: los centros, servicios y unidades de referencia del Sistema Nacional de Salud. sanidad.gob.esJ2
- Ministerio de Sanidad. El protocolo común para los tratamientos de alta complejidad del Consejo Interterritorial (10/07/2026). sanidad.gob.esC2
- Ministerio de Sanidad. Informe público sobre la decisión de inclusión de sotatercept en la prestación farmacéutica (22/12/2025). sanidad.gob.es (PDF)C2
- Ministerio de Sanidad. Manual de BIFIMED: qué quiere decir cada campo (versión 1.1, 01/03/2023). sanidad.gob.es (PDF)C2
- Ministerio de Sanidad. Ministerio de Sanidad: criterios para designar los CSUR de hipertensión pulmonar compleja (CSUR 59). sanidad.gob.es (PDF)H2J2
- Ministerio de Sanidad. Relación de los CSUR designados del Sistema Nacional de Salud, noviembre de 2026. sanidad.gob.es (PDF)J2
- Ministerio de Sanidad. Área de trasplantes de los CSUR. sanidad.gob.esJ2
- Boletín Oficial del Estado (BOE). Orden SCO/227/2007, de 24 de enero, por la que se aprueba y publica el programa formativo de la especialidad de Medicina Interna. Consultado el 18/11/2026. boe.esD3
- Boletín Oficial del Estado (BOE). Orden SCO/1259/2007, de 13 de abril, por la que se aprueba y publica el programa formativo de la especialidad de Cardiología. Consultado el 15/11/2026. boe.esD3
- Boletín Oficial del Estado (BOE). Orden SAS/2855/2009, de 9 de octubre (BOE núm. 258, de 26 de octubre de 2009). boe.esD3
- Boletín Oficial del Estado (BOE). Orden SCO/2605/2008, de 1 de septiembre (BOE núm. 223, de 15 de septiembre de 2008). boe.esD3
- Boletín Oficial del Estado (BOE). Real Decreto 577/2013, de 26 de julio, por el que se regula la farmacovigilancia de medicamentos de uso humano (BOE, texto consolidado). boe.esI2
- Agencia Europea de Medicamentos (EMA). Buscador de medicamentos. Consultado el 15/11/2026. ema.europa.euG5
- Food and Drug Administration (FDA, Estados Unidos). Drugs@FDA: base de datos de los medicamentos aprobados por la FDA. Consultado el 15/11/2026. accessdata.fda.govG5
Estudios registrados (ClinicalTrials.gov) (86)
- ADVANCE EXTENSION. A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension. ClinicalTrials.gov, NCT03683186; con reclutamiento por invitación; fase 3; 1.000 participantes previstos; variable principal prevista para diciembre de 2026. Consultado el 18/11/2026. NCT03683186G5
- ATHENA. Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH). ClinicalTrials.gov, NCT07601295; aún sin reclutar; fase 2; 90 participantes previstos; variable principal prevista para febrero de 2030. Consultado el 18/11/2026. NCT07601295G5
- BALLOON. BPA in CTEPD Without PH. ClinicalTrials.gov, NCT06090838; en reclutamiento; 60 participantes previstos; variable principal prevista para el 31/10/2025 (fecha ya pasada). Consultado el 18/11/2026. NCT06090838G5
- BETTER COPD-PH. Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH. ClinicalTrials.gov, NCT05937854; en reclutamiento; fase 2; 126 participantes previstos; variable principal prevista para el 01/03/2029. Consultado el 18/11/2026. NCT05937854G5
- CADENCE. A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16). ClinicalTrials.gov, NCT04945460; completado; fase 2; 165 participantes; terminó el 05/09/2025. Consultado el 18/11/2026. NCT04945460C5
- CAPACITY. Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects. ClinicalTrials.gov, NCT04084678; detenido antes de tiempo; fase 3; 10 participantes; variable principal cerrada el 12/04/2023. Consultado el 18/11/2026. NCT04084678G5
- CHASE. Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome. ClinicalTrials.gov, NCT07498803; aún sin reclutar; fase 2; 40 participantes previstos; variable principal prevista para el 31/03/2028. Consultado el 18/11/2026. NCT07498803G5
- CHORUS. A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041). ClinicalTrials.gov, NCT07839585; aún sin reclutar; fase 3; 352 participantes previstos; variable principal prevista para el 08/01/2030. Consultado el 18/11/2026. NCT07839585C5G5
- COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities. ClinicalTrials.gov, NCT07245680; en reclutamiento; fase 3; 186 participantes previstos; variable principal prevista para el 14/02/2029. Consultado el 18/11/2026. NCT07245680G5
- CTREPH. Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH). ClinicalTrials.gov, NCT01416636; completado; fase 3; 105 participantes; terminó en noviembre de 2016. Consultado el 18/11/2026. NCT01416636C10
- DIRECTION. Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty. ClinicalTrials.gov, NCT07644377; aún sin reclutar; fase 3; 150 participantes previstos; variable principal prevista para el 31/01/2031. Consultado el 18/11/2026. NCT07644377G5
- EmPATH. Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension. ClinicalTrials.gov, NCT06992440; en reclutamiento; fase 2; 78 participantes previstos; variable principal prevista para julio de 2030. Consultado el 18/11/2026. NCT06992440G5
- EPIMODE. CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension. ClinicalTrials.gov, NCT07761572; aún sin reclutar; fase 2; 126 participantes previstos; variable principal prevista para el 02/02/2029. Consultado el 18/11/2026. NCT07761572G5
- ERASE PH-COPD. Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease. ClinicalTrials.gov, NCT05844462; en reclutamiento; fase 3; 200 participantes previstos; variable principal prevista para octubre de 2027. Consultado el 18/11/2026. NCT05844462G5
- GO-CTEPH. BPA vs. PEA in CTEPH. ClinicalTrials.gov, NCT05110066; en reclutamiento; 139 participantes previstos; variable principal prevista para el 01/04/2027. Consultado el 18/11/2026. NCT05110066G5
- HARMONIZE. Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023). ClinicalTrials.gov, NCT06814145; activo, sin reclutar; fase 2; 440 participantes previstos; variable principal prevista para el 10/08/2035. Consultado el 18/11/2026. NCT06814145G5
- HYPERION. Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13). ClinicalTrials.gov, NCT04811092; detenido antes de tiempo; fase 3; 321 participantes; variable principal cerrada el 03/04/2025. Consultado el 18/11/2026. NCT04811092C5
- ILLUMINATE. Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH). ClinicalTrials.gov, NCT07318597; en reclutamiento; fase 2; 99 participantes previstos; variable principal prevista para el 27/02/2028. Consultado el 18/11/2026. NCT07318597G5
- IMPACT-CTEPH. Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension. ClinicalTrials.gov, NCT04780932; completado; fase 2/3; 96 participantes; terminó el 03/07/2025. Consultado el 18/11/2026. NCT04780932G5
- IMPROVE-PAH. An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH). ClinicalTrials.gov, NCT07365332; en reclutamiento; fase 3; 486 participantes previstos; variable principal prevista para junio de 2029. Consultado el 18/11/2026. NCT07365332G5
- INSIGNIA-PH-COPD. Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD. ClinicalTrials.gov, NCT05612035; activo, sin reclutar; fase 2; 129 participantes; variable principal cerrada el 09/04/2026. Consultado el 18/11/2026. NCT05612035G5
- LEVEL. LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF. ClinicalTrials.gov, NCT05983250; activo, sin reclutar; fase 3; 230 participantes previstos; variable principal cerrada el 30/06/2026. Consultado el 18/11/2026. NCT05983250G5
- LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2. ClinicalTrials.gov, NCT07288398; activo, sin reclutar; fase 3; 540 participantes previstos; variable principal prevista para el 30/06/2028. Consultado el 18/11/2026. NCT07288398G5
- LIGHTRAY. A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024). ClinicalTrials.gov, NCT06664801; completado; fase 2; 164 participantes; terminó el 20/11/2025. Consultado el 18/11/2026. NCT06664801G5
- LIGHTRAY EXT. A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION). ClinicalTrials.gov, NCT06925750; activo, sin reclutar; fase 2; 130 participantes previstos; variable principal prevista para el 16/06/2028. Consultado el 18/11/2026. NCT06925750G5
- METH-FOCUS. Sotatercept in the Treatment of Methamphetamine-Associated Pulmonary Arterial Hypertension. ClinicalTrials.gov, NCT07938294; aún sin reclutar; fase 4; 20 participantes previstos; variable principal prevista para el 01/09/2028. Consultado el 18/11/2026. NCT07938294G5
- MOONBEAM. Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008). ClinicalTrials.gov, NCT05587712; en reclutamiento; fase 2; 42 participantes previstos; variable principal prevista para el 21/09/2028. Consultado el 18/11/2026. NCT05587712G5
- PALM-ILD. Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD). ClinicalTrials.gov, NCT07179380; en reclutamiento; fase 3; 344 participantes previstos; variable principal prevista para el 30/12/2028. Consultado el 18/11/2026. NCT07179380G5
- PALM-PAH. A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH). ClinicalTrials.gov, NCT07481981; en reclutamiento; fase 3; 344 participantes previstos; variable principal prevista para el 28/12/2028. Consultado el 18/11/2026. NCT07481981G5
- PALM-PPF. A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF). ClinicalTrials.gov, NCT07805785; en reclutamiento; fase 3; 800 participantes previstos; variable principal prevista para el 31/08/2030. Consultado el 18/11/2026. NCT07805785G5
- PHocus. A Study of Mosliciguat in PH-ILD. ClinicalTrials.gov, NCT06635850; activo, sin reclutar; fase 2; 135 participantes; variable principal cerrada el 26/05/2026. Consultado el 18/11/2026. NCT06635850G5
- PHrontier. A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier). ClinicalTrials.gov, NCT07816185; en reclutamiento; fase 3; 376 participantes previstos; variable principal prevista para el 28/01/2029. Consultado el 18/11/2026. NCT07816185G5
- PreVail-PH2. Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study). ClinicalTrials.gov, NCT06052072; con reclutamiento por invitación; 50 participantes previstos; variable principal prevista para junio de 2027. Consultado el 18/11/2026. NCT06052072G5
- PreVailPH2 OUS. Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 OUS Study). ClinicalTrials.gov, NCT06495970; en reclutamiento; 20 participantes previstos; variable principal prevista para el 30/11/2025 (fecha ya pasada). Consultado el 18/11/2026. NCT06495970G5
- PROSERA. Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA). ClinicalTrials.gov, NCT05934526; completado; fase 3; 390 participantes; terminó el 27/11/2025. Consultado el 18/11/2026. NCT05934526G5
- PULSAR. A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH). ClinicalTrials.gov, NCT03496207; completado; fase 2; 106 participantes; terminó el 09/03/2022. Consultado el 18/11/2026. NCT03496207C5
- Re-PHIRE. A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2. ClinicalTrials.gov, NCT05737940; completado; fase 2; 260 participantes; terminó el 15/07/2025. Consultado el 18/11/2026. NCT05737940G5
- Re-Spire. A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD. ClinicalTrials.gov, NCT07285655; en reclutamiento; fase 3; 344 participantes previstos; variable principal prevista para julio de 2029. Consultado el 18/11/2026. NCT07285655G5
- RECOMPENSE. Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE). ClinicalTrials.gov, NCT06658522; en reclutamiento; fase 4; 20 participantes previstos; variable principal prevista para el 01/05/2026 (fecha ya pasada). Consultado el 18/11/2026. NCT06658522G5
- RED-HEART. Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART). ClinicalTrials.gov, NCT06922240; en reclutamiento; fase 3; 68 participantes previstos; variable principal prevista para el 30/10/2026 (fecha ya pasada). Consultado el 18/11/2026. NCT06922240G5
- REVAMP-PH. Repurposing Valsartan May Protect Against Pulmonary Hypertension. ClinicalTrials.gov, NCT06053580; en reclutamiento; fase 2; 60 participantes previstos; variable principal prevista para el 01/07/2027. Consultado el 18/11/2026. NCT06053580G5
- ROCSTAR. A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY). ClinicalTrials.gov, NCT07175038; en reclutamiento; fase 2; 40 participantes previstos; variable principal prevista para marzo de 2027. Consultado el 18/11/2026. NCT07175038G5
- SERANATA. Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD). ClinicalTrials.gov, NCT07181382; suspendido; fase 3; 480 participantes previstos; variable principal prevista para diciembre de 2028. Consultado el 18/11/2026. NCT07181382G5
- SERIES. Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT). ClinicalTrials.gov, NCT07462260; completado; fase 2/3; 100 participantes; terminó el 23/09/2026. Consultado el 18/11/2026. NCT07462260G5
- SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension. ClinicalTrials.gov, NCT07266519; aún sin reclutar; fase 2; 25 participantes previstos; variable principal prevista para octubre de 2028. Consultado el 18/11/2026. NCT07266519G5
- SOTERIA. A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038). ClinicalTrials.gov, NCT04796337; activo, sin reclutar; fase 3; 815 participantes previstos; variable principal prevista para el 07/12/2028. Consultado el 18/11/2026. NCT04796337C5
- SPHINX. A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. ClinicalTrials.gov, NCT03942211; detenido antes de tiempo; fase 2; 10 participantes; variable principal cerrada el 19/04/2023. Consultado el 18/11/2026. NCT03942211G5
- SuMILE. A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy. ClinicalTrials.gov, NCT07356778; en reclutamiento; fase 4; 36 participantes previstos; variable principal prevista para el 31/08/2027. Consultado el 18/11/2026. NCT07356778G5
- SUMMIT 201. Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD). ClinicalTrials.gov, NCT07923591; aún sin reclutar; fase 2; 40 participantes previstos; variable principal prevista para mayo de 2028. Consultado el 18/11/2026. NCT07923591G5
- TETON-OLE. Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease. ClinicalTrials.gov, NCT04905693; con reclutamiento por invitación; fase 3; 1.850 participantes previstos; variable principal prevista para diciembre de 2029. Consultado el 18/11/2026. NCT04905693G5
- TETON-PPF. Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF). ClinicalTrials.gov, NCT05943535; en reclutamiento; fase 3; 698 participantes previstos; variable principal prevista para noviembre de 2027. Consultado el 18/11/2026. NCT05943535G5
- The PULSE-LHD. A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease. ClinicalTrials.gov, NCT07214376; en reclutamiento; 750 participantes previstos; variable principal prevista para el 31/12/2029. Consultado el 18/11/2026. NCT07214376G5
- TRANSCEND. A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations. ClinicalTrials.gov, NCT07612657; aún sin reclutar; fase 3; 300 participantes previstos; variable principal prevista para el 31/05/2028. Consultado el 18/11/2026. NCT07612657G5
- TROPOS. A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study). ClinicalTrials.gov, NCT05975905; detenido antes de tiempo; fase 2; 113 participantes; variable principal cerrada el 05/03/2025. Consultado el 18/11/2026. NCT05975905G5
- UNISUS. Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension. ClinicalTrials.gov, NCT04273945; activo, sin reclutar; fase 3; 935 participantes; variable principal cerrada el 07/10/2025. Consultado el 18/11/2026. NCT04273945G5
- ViTAL-PH. A Trial of "APL-9796'' in Adults With Pulmonary Hypertension. ClinicalTrials.gov, NCT06846554; en reclutamiento; fase 2; 48 participantes previstos; variable principal prevista para el 30/08/2027. Consultado el 18/11/2026. NCT06846554G5
- WATERLOO. Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO). ClinicalTrials.gov, NCT07700303; aún sin reclutar; 78 participantes previstos; variable principal prevista para el 30/03/2028. Consultado el 18/11/2026. NCT07700303G5
- WINDWARD. Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward). ClinicalTrials.gov, NCT06475781; en reclutamiento; fase 2; 126 participantes previstos; variable principal prevista para febrero de 2028. Consultado el 18/11/2026. NCT06475781G5
- ZENITH. A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH). ClinicalTrials.gov, NCT04896008; completado; fase 3; 173 participantes; terminó el 26/07/2024. Consultado el 18/11/2026. NCT04896008C5
- A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD). ClinicalTrials.gov, NCT07441278; en reclutamiento; fase 2; 177 participantes previstos; variable principal prevista para el 14/09/2028. Consultado el 18/11/2026. NCT07441278G5
- A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD. ClinicalTrials.gov, NCT04691154; activo, sin reclutar; fase 3; 28 participantes; variable principal cerrada el 20/03/2025. Consultado el 18/11/2026. NCT04691154G5
- A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy. ClinicalTrials.gov, NCT07593027; en reclutamiento; fase 1/2; 120 participantes previstos; variable principal prevista para el 31/10/2027. Consultado el 18/11/2026. NCT07593027G5
- A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults. ClinicalTrials.gov, NCT07143448; en reclutamiento; fase 1/2; 90 participantes previstos; variable principal prevista para marzo de 2028. Consultado el 18/11/2026. NCT07143448G5
- A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD. ClinicalTrials.gov, NCT07333183; en reclutamiento; fase 2; 20 participantes previstos; variable principal prevista para diciembre de 2026. Consultado el 18/11/2026. NCT07333183G5
- A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032). ClinicalTrials.gov, NCT07646860; en reclutamiento; fase 2; 6 participantes previstos; variable principal prevista para el 24/05/2029. Consultado el 18/11/2026. NCT07646860G5
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR). ClinicalTrials.gov, NCT04576988; completado; fase 3; 324 participantes; terminó el 26/08/2022. Consultado el 18/11/2026. NCT04576988C5
- A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study). ClinicalTrials.gov, NCT06616974; activo, sin reclutar; fase 2; 191 participantes previstos; variable principal prevista para el 24/11/2026. Consultado el 18/11/2026. NCT06616974G5
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension. ClinicalTrials.gov, NCT05147805; completado; fase 2; 102 participantes; terminó el 27/03/2025. Consultado el 18/11/2026. NCT05147805G5
- A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489. ClinicalTrials.gov, NCT07073820; detenido antes de tiempo; fase 2; 42 participantes; variable principal cerrada el 09/10/2026. Consultado el 18/11/2026. NCT07073820G5
- A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension. ClinicalTrials.gov, NCT06137742; completado; fase 1/2; 97 participantes; terminó el 31/07/2026. Consultado el 18/11/2026. NCT06137742G5
- A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B). ClinicalTrials.gov, NCT06649110; en reclutamiento; fase 1/2; 232 participantes previstos; variable principal prevista para el 29/11/2028. Consultado el 18/11/2026. NCT06649110G5
- Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH). ClinicalTrials.gov, NCT07441200; en reclutamiento; fase 2; 135 participantes previstos; variable principal prevista para el 01/08/2028. Consultado el 18/11/2026. NCT07441200G5
- Colchicine in Pulmonary Artery Hypertension Patients. ClinicalTrials.gov, NCT07907757; aún sin reclutar; fase 2; 60 participantes previstos; variable principal prevista para el 30/01/2027. Consultado el 18/11/2026. NCT07907757G5
- Evaluation of the Efficacy and Safety of Oxacom in Patients With Pulmonary Arterial Hypertension. ClinicalTrials.gov, NCT06683040; activo, sin reclutar; fase 2/3; 260 participantes; variable principal prevista para el 31/12/2027. Consultado el 18/11/2026. NCT06683040G5
- HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction. ClinicalTrials.gov, NCT07123779; en reclutamiento; fase 1/2; 126 participantes previstos; variable principal prevista para enero de 2029. Consultado el 18/11/2026. NCT07123779G5
- LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD). ClinicalTrials.gov, NCT05798923; en reclutamiento; fase 2; 85 participantes previstos; variable principal prevista para marzo de 2028. Consultado el 18/11/2026. NCT05798923G5
- LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH). ClinicalTrials.gov, NCT07886554; aún sin reclutar; fase 2; 60 participantes previstos; variable principal prevista para diciembre de 2028. Consultado el 18/11/2026. NCT07886554G5
- Long-Term Open-Label Extension Study of Oral Levosimendan. ClinicalTrials.gov, NCT07436689; con reclutamiento por invitación; fase 3; 800 participantes previstos; variable principal prevista para marzo de 2029. Consultado el 18/11/2026. NCT07436689G5
- Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT). ClinicalTrials.gov, NCT06274801; en reclutamiento; fase 3; 330 participantes previstos; variable principal prevista para diciembre de 2026. Consultado el 18/11/2026. NCT06274801G5
- Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients. ClinicalTrials.gov, NCT03624010; completado; fase 2; 35 participantes; terminó el 25/04/2023. Consultado el 18/11/2026. NCT03624010G5
- Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH). ClinicalTrials.gov, NCT07632898; aún sin reclutar; fase 3; 484 participantes previstos; variable principal prevista para el 30/06/2030. Consultado el 18/11/2026. NCT07632898G5
- Spironolactone for Pulmonary Arterial Hypertension. ClinicalTrials.gov, NCT01712620; en reclutamiento; fase 2; 70 participantes previstos; variable principal prevista para el 31/12/2031. Consultado el 18/11/2026. NCT01712620G5
- Study for Evaluation of Safety and Efficacy of PADN to Treat Combined Post- and Pre- Capillary Pulmonary Hypertension Associated With Chronic Heart Failure(PADN-CpcPH-PILOT). ClinicalTrials.gov, NCT05996562; completado; 30 participantes; terminó el 15/01/2026. Consultado el 18/11/2026. NCT05996562G5
- Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension. ClinicalTrials.gov, NCT05135000; detenido antes de tiempo; fase 2; 47 participantes; variable principal cerrada el 20/03/2024. Consultado el 18/11/2026. NCT05135000G5
- Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease. ClinicalTrials.gov, NCT07473700; en reclutamiento; fase 2; 25 participantes previstos; variable principal prevista para el 21/11/2027. Consultado el 18/11/2026. NCT07473700G5
- TROPHY PAH Pivotal Study - TReatment of Pulmonary HYpertension for PAH Pivotal Study. ClinicalTrials.gov, NCT04570228; en estado desconocido; 205 participantes previstos; variable principal prevista para el 01/12/2023 (fecha ya pasada). Consultado el 18/11/2026. NCT04570228G5
